- Alagos Therapeutics is advancing **pevifoscovir (PEVY)**, a next-generation capsid assembly modulator for chronic hepatitis B virus (CHB) infection, which demonstrates **picomolar potency** and a dual mechanism of action, including direct effects on reducing cccDNA.  **[0001799448_2193224_0]** **[0001799448_2193224_1]** 
- In a 96-week study, PEVY achieved **100% viral suppression** (below 10 international units of HBV DNA) in e-negative patients and 60% in e-positive patients at week 48, with e-positive patients reaching 100% by week 96.  **[0001799448_2193224_2]** **[0001799448_2193224_7]** 
- The company has initiated the **Phase 2 b-SUPREME trial** for PEVY, designed as a monotherapy superiority study, with interim analyses expected in **2026** and top-line data in **2027**.  **[0001799448_2193224_3]** **[0001799448_2193224_4]** **[0001799448_2193224_7]** 
- Alagos is also developing **ALG-055009**, a thyroid hormone receptor beta agonist for MASH, which is **50 to 100 times more potent** than Resmetirom and showed up to a **46% reduction in fat** in a Phase 2a study.  **[0001799448_2193224_8]** 
- The company is currently in **partnering discussions** for ALG-055009, with an announcement hoped for in the **first half of next year**, and sees a potential role for the drug in obesity in combination with incretins.  **[0001799448_2193224_9]** **[0001799448_2193224_10]**

Alagos Therapeutics Discusses Lead Programs PEVY for HBV and ALG-055009 for MASH at H.C. Wainwright Conference

- Aligos Therapeutics is developing **PEVI/PHOSCOVIR (PEVI)** for chronic hepatitis B virus (CHB), which achieved a **100% response rate** (patients below 10 IU of HBV DNA) in both E antigen negative and positive patients at 96 weeks in a prior study.  **[0001799448_2193207_2]** **[0001799448_2193207_5]** **[0001799448_2193207_7]** 
- The **B Supreme Phase II study** for PEVI has commenced across 14 countries, with regulatory acceptance for chronic suppression as the primary endpoint; interim analyses are projected for **H1 2026** and top-line data for **2027**.  **[0001799448_2193207_3]** **[0001799448_2193207_4]** **[0001799448_2193207_7]** 
- For metabolic dysfunction-associated steatohepatitis (MASH), Aligos is advancing **ALG-055009**, a thyroid hormone receptor beta agonist that demonstrated up to a **46% reduction in fat** in a Phase IIa study, approximately double the efficacy of resmetirom in a comparable study.  **[0001799448_2193207_0]** **[0001799448_2193207_8]** 
- Aligos is actively pursuing partnering discussions for ALG-055009, with an anticipated deal announcement in the **first half of 2026**.  **[0001799448_2193207_10]**

Aligos Therapeutics (ALGS)